Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Context Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CNTX
Nasdaq
8731
https://www.contexttherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Context Therapeutics Inc
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
- Apr 1st, 2024 11:30 am
Companies Like Context Therapeutics (NASDAQ:CNTX) Could Be Quite Risky
- Mar 27th, 2024 12:50 pm
Context Therapeutics Reports Full Year 2023 Operating and Financial Results
- Mar 21st, 2024 11:43 am
Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results
- Nov 9th, 2023 9:15 pm
Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76
- Oct 31st, 2023 1:00 pm
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
- Oct 24th, 2023 4:30 pm
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Sep 27th, 2023 1:00 pm
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update
- Aug 10th, 2023 6:19 pm
Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results
- Aug 9th, 2023 8:10 pm
Context Therapeutics to Participate in Two August 2023 Investor Conferences
- Aug 1st, 2023 11:30 am
Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
- Jun 3rd, 2023 12:27 pm
Context Therapeutics Reports First Quarter 2023 Operating and Financial Results
- May 10th, 2023 8:39 pm
Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting
- Apr 24th, 2023 4:01 pm
Scroll